1. The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience

   • László Gulácsi

   Editorial 14 April 2007 Pages: 83 - 88

2. Pharmacoeconomic studies in Italy: a critical review of the literature

   • D. Cornago
   • L. Li Bassi
   • L. Garattini

   Original paper 21 December 2006 Pages: 89 - 95

   

3. The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management

   • Vesna Bjegovic
   • Zorica Terzic
   • Ulrich Laaser

   Original paper 13 January 2007 Pages: 97 - 103

4. Patients’ willingness to pay for electronic communication with their general practitioner

   • Trine Strand Bergmo
   • Silje Camilla Wangberg

   Original paper 21 December 2006 Pages: 105 - 110

   

5. Systematic review of economic evaluations and cost analyses of guideline implementation strategies

   • Luke Vale
   • Ruth Thomas
   • Jeremy Grimshaw

   Original paper 09 March 2007 Pages: 111 - 121

6. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

   • Maureen P. M. H. Rutten-van Mölken
   • Jan B. Oostenbrink
   • Brigitta U. Monz

   Original paper Open access 17 March 2007 Pages: 123 - 135

   

7. The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49

   • Richard P. A. Norman
   • D. Gareth Evans
   • Kenneth C. Young

   Original paper 09 March 2007 Pages: 137 - 144

   

8. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system

   • K. Le Lay
   • E. Myon
   • R. Launois

   Original Paper 28 February 2007 Pages: 145 - 151

   

9. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany

   • Sara K. Sheriff
   • K. Ulrich Petry
   • Christopher C. Santas

   Original paper 17 February 2007 Pages: 153 - 160

   

10. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

    • Andrew J. Palmer
    • William J. Valentine
    • Noemi Muszbek

    Original Paper 20 January 2007 Pages: 161 - 168

    

11. Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi

    • Joshua Cohen

    Discussion 20 April 2007 Pages: 169 - 170

12. Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen

    • Livio Garattini

    Discussion 20 April 2007 Pages: 171 - 171

13. Discussion point: should governments buy drug patents?

    • Juan del Llano

    Pricing and Reimbursement Systems in Europe 16 January 2007 Pages: 173 - 177